Oryzon to Present its LSD1 programs in Acute Leukemias and in Neurodegenerative disorders at the GTC's 3rd Epigenetics in Drug Discovery conference in Boston

Barcelona, May 2th, 2013. Oryzon announced today that Dr. Tamara Maes will present the latest advances of its LSD1 program in hematological malignancies at GTC's 3rd Epigenetics in Drug Discovery conference in the session *Drug Discovery in Epigenetics:* on May 8-10 at the Hyatt Regency in Boston, MA.

Barcelona, May 2nd, 2013. Dr. Maes' presentation will occur on Thursday, May 9, at 15:30 pm under the title "**Prospects of LSD1 Inhibitors for the Treatment of Cancer and Neurodegenerative Diseases".** Lysine specific demethylase 1 (LSD1, KDM1A), is an epigenetic modulator able that regulates gene expression by demethylating histones. LSD1 forms part of protein complexes involved in transcriptional regulation, and mis-regulation of these transcriptional complexes may result in disease.

Molecules discovered and developed by Oryzon were efficient in the treatment of acute myeloid leukemia (AML). Our candidate, ORY-1001, is an enantiomerically pure LSD1 inhibitor that is >1000x stronger than tranylcypromine, highly selective over related enzymes such as MAO-A/B, IL4I1, SMOX and LSD2 and has excellent pharmacological characteristics. ORY-1001 reduces leukemic stem cell potential, potently inhibits colony formation, overcomes the differentiation block in AML cell lines, and induces apoptosis / inhibits proliferation at sub-nanomolar concentrations in selected AML cell lines.ORY-1001 has successfully passed the regulatory toxicology IND enabling studies. The company expects to move its compounds to Clinical Phase I/IIa in 2013.

The potential use of LSD1 inhibitors is not limited to oncological disease. LSD1 is well known to partner with Co-REST and REST/NRSF, a gene involved in the repression of neuronal genes in non-neuronal cells. Aberrant levels or activity of REST/Co-REST complexes has been implicated in different neurodegenerative diseases like Huntington's disease, Rett syndrome and increased REST expression was found in the brain of Alzheimer disease patients. Data in animal models of these neurodegenerative disorders obtained with our CNS candidate ORY-2001 will be presented.

The GTC's 3rd Epigenetics in Drug Discovery conference is the only epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel epigenetic mechanisms, therapeutics, developments, biomarkers and diagnostics. Venture Capitalists will also join the conference to discuss investment opportunities and what they look for in the epigenetics space.

Some key discussions around epigenetics drug discovery at the conference include: 1) The role of epigenetics in human diseases such as cancer, leukaemia, neurodegenerative conditions, neuropsychiatric disorders, inflammation, etc. 2) Novel mechanisms, biomarkers, technologies and diagnostics for epigenetics drug discovery 3) Cutting edge research from GlaxoSmithKline, Epizyme, Genentech, Constellation, Astex, Cellzome, RaNA Therapeutics, Pfizer, Harvard, Massachusetts Institute of Technology, etc

Epigenetics is a hot spot field in the pharmaceutical industry. It is predicted that world revenues for epigenetic therapies and technologies will reach $2.73bn in 2015 and that the overall market will grow with a CAGR of 16% between 2010 and 2015. Therapies will remain the largest source of revenue in the epigenetics market. The deal activity on the field is intense.

Oryzon Genomics is the global leader in Histone Lysine Demethylases with an special emphasis on Lysine Specific Demethylases (LSD1 and LSD2). LSD1 is a flavin dependent amine oxidase capable of selective demethylation of Lys-4 of histone H3. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. Oryzon has a wide drug-discovery program on LSD1 with around 900 compounds and two preclinical candidates. According to Carlos Buesa, C.E.O. of the company. "*Oryzon's compounds are by far the most potent LSD1 inhibitors described, and we have identified now a subset of diseases in which this mechanism looks particularly efficient. The company has a dominant patent position in LSD1 with 18 patent families and we are really happy to communicate to the Epigenetic community our progresses and the potential of LSD1 as therapeutic target in hematological cancers. For any company willing to play a role in these indications we are the partner of choice*"

About Oryzon

Founded in 2000, Oryzon (www.oryzon.com) has one of the most complete technological platforms for biomarker identification in Europe. With a strong specialization in genomics, proteomics and bioinformatics, the company identifies biomarkers for a variety of neoplasic and neurodegenerative diseases. The company has a powerful platform for biomarker and target validation which includes technologies such as RNAi, microarrays, phage display and a structural genomic platform with a fragment screening approach (NMR and X ray crystallography). Oryzon develops new drugs and monoclonal antibodies against targets identified in its biomarker discovery programs but also develops diagnostic products.

For further information, please contact:

Emili Torrell
Business Development Officer
Tel. +34 93 515 13 13,
etorrell@oryzon.com